Drugs / Bmab 1200
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06738277 | Jan → Jul 2025 | psoriasis | Biocon Biologics UK Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05335356 | Jun 2022 → Jan 2023 | psoriasis | Biocon Biologics UK Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bmab 1200 | “Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized,...” PMID 40708530 ↗ Jul 2025 |
| Known as | Ustekinumab | “Bmab 1200 (Biosimilar Ustekinumab)” NCT06738277 ↗ |
| Route | Subcutaneous | “Route of Administration: Subcutaneous” NCT06738277 ↗ |